Latest Capital Structure News

Yojee Limited has raised up to AUD 9 million through an oversubscribed placement and share purchase plan, aiming to fast-track the commercial expansion of its MOSAIC freight forwarding platform and TCMS transport software.

Australian Rare Earths (ASX: AR3) has delivered a standout Pre-Feasibility Study and maiden Ore Reserve for its Koppamurra project, underpinning a low-capital, high-return rare earths development. Meanwhile, pilot processing advances and a new niobium-REE discovery at Overland add momentum.

Stelar Metals has fast-tracked exploration at its newly acquired Hill of Leaders Tungsten Project in the Northern Territory, reporting multiple high-grade tungsten assays exceeding 1% WO₃ and preparing for its maiden Reverse Circulation drilling campaign.

Eden Innovations reported strong EdenCrete® trial results in India and North America, strategic hires for EdenShield® in defence markets, and completed a $4.05 million placement, ending the quarter debt-free with $5.2 million cash.

Tolu Minerals has delivered its most intensive drilling campaign at Tolukuma, uncovering two new high-grade gold veins and maintaining a strong cash position as it targets first production by early 2027.

Theta Gold Mines has locked in a US$90 million senior secured bond and raised US$18.6 million in equity, pushing its TGME Gold Project construction steadily towards first gold in early 2027.

Minbos Resources has appointed a new CEO, secured key funding tranches, and progressed construction at its flagship Cabinda Phosphate Project, targeting plant inauguration by December 2026.

Charger Metals has expanded its Medcalf lithium resource to 10.6 million tonnes at 1.0% Li2O, backed by strong metallurgical results and a fresh $3.75 million cash injection from selling its Bynoe project.

Riedel Resources has transformed into a multi-project gold explorer with the acquisition of controlling interests in the Cosmo and Mt Venn projects in Western Australia, complementing its Kingman asset in Arizona. The company is gearing up for maiden drilling and expanded exploration across its portfolio.

Enlitic slashed its net operating cash outflow by 76% in Q2 FY26 and secured binding commitments for a A$15 million conditional placement alongside convertible note conversions, positioning the company with a pro forma cash balance of about A$18 million and a debt-free balance sheet.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.